May 31, 2019 Conference
Precis: Previously a blinding disease with poor treatment options, wet age related macular degeneration now has many powerful therapeutic options available. Specifically, anti-vascular endothelial growth factor agents have played a central role in greatly diminishing the visual impact of this disease. Clinical trials have estimated that by using agents such as bevacizumab, ranibizumab and aflibercept, greater than 90% of patients lose less than 15 ETDRS letters after one year. However, despite the successes of these agents, durability and sustainability of these treatments remain problematic for both patients and their providers. Promising results from recent phase 3 trials gives hope that new agents such as brolucizumab and abicipar may help address some of the current short comings in current therapy.